Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Xiujiao Deng, Jinghao Wang, Shanshan Yu, Suiyi Tan, Tingting Yu, Qiaxin Xu, Nenghua Chen, Siqi Zhang, Ming-Rong Zhang, Kuan Hu, Zeyu Xiao

Exploration ›› 2024, Vol. 4 ›› Issue (3) : 20230090-24.

PDF
Exploration ›› 2024, Vol. 4 ›› Issue (3) : 20230090-24. DOI: 10.1002/EXP.20230090
REVIEW

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Author information +
History +

Abstract

Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well-being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface-modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over-expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand-modified nanoparticle systems targeting atherosclerosis by specifically targeting signaturemolecules in the hope of precise treatment at themolecular level andconcludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

Keywords

atherosclerosis / drug delivery / ligand-modified / nano-drugs / targeted therapies

Cite this article

Download citation ▾
Xiujiao Deng, Jinghao Wang, Shanshan Yu, Suiyi Tan, Tingting Yu, Qiaxin Xu, Nenghua Chen, Siqi Zhang, Ming-Rong Zhang, Kuan Hu, Zeyu Xiao. Advances in the treatment of atherosclerosis with ligand-modified nanocarriers. Exploration, 2024, 4(3): 20230090‒24 https://doi.org/10.1002/EXP.20230090

RIGHTS & PERMISSIONS

2023 2023 The Authors. Exploration published by Henan University and John Wiley & Sons Australia, Ltd.
PDF

Accesses

Citations

Detail

Sections
Recommended

/